The stability delta requirements for human pharmaceuticals in the European Community (EC) are based on a series of Directive and Regulation requirements and on a series of advisory guidelines that have been developed and adapted through the International Conference an Harmonization (ICH) procedures or, where there is no relevant ICH project, through the Committee for Proprietary: Medicinal Products (CPMP). There are relevant requirements that cover new drugs and finished products containing them and also for existing active ingredients and products containing them. The sources of the relevant information and the darn requirements are discussed and summarized.
引用
收藏
页码:831 / 856
页数:26
相关论文
共 1 条
[1]
*COMM PROPR MED PR, 1998, RUL GOV MED PROD E A, V3, P129